Cargando…
Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids
Minor neurological symptoms such as anosmia are relatively common manifestations of coronavirus disease 2019 (COVID-19). However, severe affection of the central nervous system (CNS) occurs in a minority of cases and its treatment and pathophysiology is not yet well understood. It has been described...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501896/ https://www.ncbi.nlm.nih.gov/pubmed/34660051 http://dx.doi.org/10.7759/cureus.17845 |
_version_ | 1784580768556646400 |
---|---|
author | Pizzato Tondo, Lucca Beck Paglioli Neto, Eduardo Arpini, Soel Passos, Giordani Becker, Jefferson |
author_facet | Pizzato Tondo, Lucca Beck Paglioli Neto, Eduardo Arpini, Soel Passos, Giordani Becker, Jefferson |
author_sort | Pizzato Tondo, Lucca |
collection | PubMed |
description | Minor neurological symptoms such as anosmia are relatively common manifestations of coronavirus disease 2019 (COVID-19). However, severe affection of the central nervous system (CNS) occurs in a minority of cases and its treatment and pathophysiology is not yet well understood. It has been described that encephalitis due to COVID-19 may be caused by the proinflammatory state due to the cytokine storm or direct invasion of the virus in the CNS. Here we present a case of a 66-year-old man with bipolar disorder and moderate respiratory COVID-19 symptoms who presented to the emergency department with a decreased level of consciousness. Brain computerized tomography (CT) showed no acute pathology. A thorough investigation of other possible causes of CNS affection was negative. The patient was treated with pulse therapy with methylprednisolone and presented a significant improvement of his neurological condition, being discharged with a complete neurological recovery five days after the start of the treatment. This case illustrates the importance of a high index of suspicion in diagnosing severe CNS impairment in mild respiratory COVID-19 cases. Also, this case corroborates with previous reports of glucocorticoid response in CNS impairment associated with COVID-19, although more robust studies are required to confirm this relation. |
format | Online Article Text |
id | pubmed-8501896 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-85018962021-10-14 Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids Pizzato Tondo, Lucca Beck Paglioli Neto, Eduardo Arpini, Soel Passos, Giordani Becker, Jefferson Cureus Neurology Minor neurological symptoms such as anosmia are relatively common manifestations of coronavirus disease 2019 (COVID-19). However, severe affection of the central nervous system (CNS) occurs in a minority of cases and its treatment and pathophysiology is not yet well understood. It has been described that encephalitis due to COVID-19 may be caused by the proinflammatory state due to the cytokine storm or direct invasion of the virus in the CNS. Here we present a case of a 66-year-old man with bipolar disorder and moderate respiratory COVID-19 symptoms who presented to the emergency department with a decreased level of consciousness. Brain computerized tomography (CT) showed no acute pathology. A thorough investigation of other possible causes of CNS affection was negative. The patient was treated with pulse therapy with methylprednisolone and presented a significant improvement of his neurological condition, being discharged with a complete neurological recovery five days after the start of the treatment. This case illustrates the importance of a high index of suspicion in diagnosing severe CNS impairment in mild respiratory COVID-19 cases. Also, this case corroborates with previous reports of glucocorticoid response in CNS impairment associated with COVID-19, although more robust studies are required to confirm this relation. Cureus 2021-09-09 /pmc/articles/PMC8501896/ /pubmed/34660051 http://dx.doi.org/10.7759/cureus.17845 Text en Copyright © 2021, Pizzato Tondo et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Neurology Pizzato Tondo, Lucca Beck Paglioli Neto, Eduardo Arpini, Soel Passos, Giordani Becker, Jefferson Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids |
title | Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids |
title_full | Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids |
title_fullStr | Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids |
title_full_unstemmed | Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids |
title_short | Encephalopathy Due to COVID-19 With Great Response to Glucocorticoids |
title_sort | encephalopathy due to covid-19 with great response to glucocorticoids |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501896/ https://www.ncbi.nlm.nih.gov/pubmed/34660051 http://dx.doi.org/10.7759/cureus.17845 |
work_keys_str_mv | AT pizzatotondolucca encephalopathyduetocovid19withgreatresponsetoglucocorticoids AT beckpagliolinetoeduardo encephalopathyduetocovid19withgreatresponsetoglucocorticoids AT arpinisoel encephalopathyduetocovid19withgreatresponsetoglucocorticoids AT passosgiordani encephalopathyduetocovid19withgreatresponsetoglucocorticoids AT beckerjefferson encephalopathyduetocovid19withgreatresponsetoglucocorticoids |